Neuronetics, Inc. (NASDAQ:STIM) EVP Sells $46,630.25 in Stock

Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan sold 12,175 shares of the business’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total transaction of $46,630.25. Following the transaction, the executive vice president now owns 388,647 shares in the company, valued at approximately $1,488,518.01. This represents a 3.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Andrew Macan also recently made the following trade(s):

• On Monday, February 10th, William Andrew Macan sold 1,970 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total value of $6,461.60.

Neuronetics Stock Performance

Shares of STIM stock opened at $4.36 on Friday. Neuronetics, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $5.07. The stock’s 50-day moving average is $2.20 and its two-hundred day moving average is $1.41. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The firm has a market cap of $132.33 million, a P/E ratio of -3.54 and a beta of 2.17.

Institutional Investors Weigh In On Neuronetics

Several large investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in Neuronetics in the fourth quarter valued at approximately $49,000. Geode Capital Management LLC raised its holdings in shares of Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after purchasing an additional 8,466 shares in the last quarter. Tradewinds LLC. bought a new position in shares of Neuronetics during the 4th quarter valued at $32,000. JPMorgan Chase & Co. lifted its stake in shares of Neuronetics by 10,954.1% in the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after purchasing an additional 54,442 shares during the last quarter. Finally, David J Yvars Group boosted its holdings in Neuronetics by 47.1% in the fourth quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after purchasing an additional 14,825 shares in the last quarter. Institutional investors own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.